FY2024 Earnings Estimate for ARTV Issued By HC Wainwright

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) – Equities researchers at HC Wainwright issued their FY2024 EPS estimates for Artiva Biotherapeutics in a report released on Monday, December 30th. HC Wainwright analyst E. White anticipates that the company will post earnings of ($6.00) per share for the year. HC Wainwright currently has a “Buy” rating and a $20.00 target price on the stock. The consensus estimate for Artiva Biotherapeutics’ current full-year earnings is ($4.68) per share. HC Wainwright also issued estimates for Artiva Biotherapeutics’ Q4 2024 earnings at ($0.74) EPS, Q1 2025 earnings at ($0.76) EPS, Q2 2025 earnings at ($0.78) EPS, Q3 2025 earnings at ($0.81) EPS, Q4 2025 earnings at ($0.86) EPS, FY2025 earnings at ($3.21) EPS, FY2026 earnings at ($0.78) EPS and FY2027 earnings at ($0.92) EPS.

Separately, Needham & Company LLC reaffirmed a “buy” rating and issued a $23.00 price objective on shares of Artiva Biotherapeutics in a research note on Wednesday, November 13th. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $21.00.

Artiva Biotherapeutics Price Performance

Shares of NASDAQ ARTV opened at $9.97 on Wednesday. Artiva Biotherapeutics has a twelve month low of $9.68 and a twelve month high of $17.31. The firm’s fifty day moving average price is $11.36.

Artiva Biotherapeutics (NASDAQ:ARTV) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.92) earnings per share for the quarter, missing the consensus estimate of ($0.68) by ($0.24).

Institutional Investors Weigh In On Artiva Biotherapeutics

A number of institutional investors have recently added to or reduced their stakes in the stock. BNP Paribas Financial Markets acquired a new stake in Artiva Biotherapeutics in the third quarter valued at approximately $42,000. MetLife Investment Management LLC acquired a new stake in shares of Artiva Biotherapeutics in the 3rd quarter worth $135,000. JPMorgan Chase & Co. purchased a new position in Artiva Biotherapeutics during the 3rd quarter worth $166,000. Barclays PLC acquired a new position in Artiva Biotherapeutics during the 3rd quarter valued at about $304,000. Finally, Charles Schwab Investment Management Inc. purchased a new stake in Artiva Biotherapeutics in the third quarter valued at about $623,000.

About Artiva Biotherapeutics

Artiva Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company’s lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma.